SEC Company Response from Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — Feb 14, 2011

Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: Feb. 14, 2011 · CIK: 0000876343 · Accession: 0000876343-11-000014

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-12830

Referenced dates: July 27, 2010

Date

August 3, 2010

Author

s/Robert W. Peabody

Form

CORRESP

Company

Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)

Letter

Securities and Exchange Commission RE: BioTime, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Definitive Proxy Statement Filed April 30, 2010 File No. 001-12830

Dear Mr. Rosenberg:

This letter is provided pursuant to your comment letter dated July 27, 2010 concerning the above-referenced Form 10-K and Proxy Statement. BioTime acknowledges that:

the company is responsible for the adequacy and accuracy of the disclosure in the filing;

staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing;

the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,
s/Robert W. Peabody

Show Raw Text

CORRESP
1
filename1.htm

    secletter_aug032010.htm

BIOTIME, INC.

1301 Harbor Bay Parkway, Suite 100

Alameda, California 94502

(510) 521-3390

August 3, 2010

Mr. Jim B. Rosenberg

Senior Assistant Chief Accountant

Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

RE:          BioTime, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2009

Definitive Proxy Statement Filed April 30, 2010

File No. 001-12830

Dear Mr. Rosenberg:

This letter is provided pursuant to your comment letter dated July 27, 2010 concerning the above-referenced Form 10-K and Proxy Statement.  BioTime acknowledges that:

·

the company is responsible for the adequacy and accuracy of the disclosure in the filing;

·

staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing;

·

the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,

s/Robert W. Peabody

Senior Vice President,

Chief Operating Officer and

Chief Financial Officer

SecProbe.io